234 Church Street
About Biohaven Pharma
230 articles with Biohaven Pharma
Biohaven Pharmaceutical Holding Company Ltd. announced that it has commenced an underwritten public offering of $300 million of its common shares.
Biohaven Announces Expanded Safety And Preliminary Preventive Efficacy Data From Ongoing Long-Term Safety Study, And Presents Case Reports Of Using Rimegepant To Successfully Treat Breakthrough Migraine Attacks In Patients Taking Preventive CGRP
Over 105,000 doses of rimegepant 75 mg have been administered in over 1,780 migraine patients in the long-term safety study to date
Phase 2/3 clinical trials of troriluzole, a glutamate modulator, in Alzheimer's disease, generalized anxiety disorder, and obsessive-compulsive disorder are all expected to complete enrollment by end of 2019
Biohaven Pharmaceuticals Reports First Quarter 2019 Financial Results And Advancements In Neuroinnovation Platforms
Secured Priority Review Voucher (PRV) enabling expedited regulatory review of rimegepant Zydis® ODT New Drug Application (NDA)
William "BJ" Jones joins Biohaven as Chief Commercial Officer, Migraine and Common Diseases
Biohaven Enrolls First Patient in Phase 2/3 Trial of BHV-3500, Third-Generation CGRP Receptor Antagonist, for the Acute Treatment of Migraine
BHV-3500 is the first CGRP receptor antagonist drug candidate to be administered in an intranasal (IN) formulation in late stage testing and is Biohaven's second drug candidate from its NOJECTION™ migraine platform
Biohaven Secures Priority Review Voucher (PRV) To Expedite Regulatory Review Of Rimegepant Zydis ODT New Drug Application
Rimegepant Zydis orally disintegrating tablet (ODT) is Biohaven's lead oral CGRP receptor antagonist drug candidate from its NOJECTION™ migraine platform
Company Announces Expanded Data From Troriluzole Phase IIb/III Long-Term Extension Study Compared To Matched Natural History Cohort
Biohaven Announces Completion of Pre-NDA Meeting With FDA for Oral CGRP Receptor Antagonist Rimegepant
-Biohaven remains on-track for new drug application (NDA) submission for rimegepant Zydis ODT and tablet formulation in 2Q2019
Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial And Recent Business Results
Positioned to submit New Drug Applications (NDA) for rimegepant Zydis ODT and tablet formulations for the acute treatment of migraine in 2Q2019
Biohaven Pharmaceutical Holding Company Ltd. announced that it received orphan drug designation from the U.S. Food and Drug Administration for its product candidate verdiperstat, a novel myeloperoxidase inhibitor, for the treatment of multiple system atrophy.
Biohaven Achieves Targeted Therapeutic Exposures of BHV-3500, a Third-Generation Small Molecule CGRP Receptor Antagonist
Phase 2 Efficacy Trial Start Planned for Second Quarter 2019
Biohaven Receives FDA May Proceed Letter For Phase 3 Clinical Trial Of BHV-3241 For Multiple System Atrophy
Biohaven Pharmaceutical Holding Company Ltd. announced the U.S. Food and Drug Administration (FDA) has notified the Company that it may proceed with its clinical investigation of BHV-3241, a novel myeloperoxidase (MPO) inhibitor, which Biohaven is developing as a potential treatment for multiple system atrophy (MSA).
Rimegepant is the first small molecule, orally administered, calcitonin gene-related peptide (CGRP) receptor antagonist potentially being developed for both the acute and preventive treatment of migraine in China
Biohaven Announces Closing Of $144M Public Offering Of Common Shares, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares
Biohaven Pharmaceutical Holding Company Ltd. announced today the closing of its underwritten public offering of 3,859,060 of its common shares, including the full exercise of the underwriters' option to purchase additional shares, at a price to the public of $37.25 per share.
Biohaven Pharmaceutical Holding Company Ltd. today announced the pricing of its underwritten public offering of 3,355,705 of its common shares at a price to the public of $37.25 per share.
Biohaven Pharmaceutical Holding Company Ltd. today announced that it has commenced an underwritten public offering of 3,000,000 of its common shares.
Over 91,000 doses of rimegepant 75mg administered across 1,780 patients with migraine
Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of Migraine
Single dose, proprietary, rimegepant Zydis ODT formulation provided rapid onset of pain relief with numerical separation from placebo as early as 15 minutes and statistically significant by 60 minutes
Biohaven Announces FDA Acceptance of 505(b)(2) NDA Filing for BHV-0223, a Novel Sublingual Delivery Form of Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
If approved, BHV-0223 would become the only formulation of riluzole that does not require swallowing tablets or liquids, offering an important delivery alternative for the standard-of-care treatment of ALS